

**UNITED STATES DEPARTMENT OF COMMERCE****Patent and Trademark Office**Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

08/823,980 03/25/97 WEINER

A 0938.002 (B&amp;W)

18M1/0819

ALISA A HARBIN  
INTELLECTUAL PROPERTY R440  
CHIRON CORPORATION  
4560 HORTON STREET  
EMERYVILLE CA 94608-2916

EXAMINER

SCHWADRON, R

ART UNIT PAPER NUMBER

1816

DATE MAILED: 08/19/97

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks**



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

09/823980

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER	
ART UNIT	PAPER NUMBER

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2).

A sequence listing was submitted in the parent application, but the following problems have been noted. Regarding the sequence listed on page 30, line 23 of the specification, said sequence is not SEQ. ID. no. 2 because the first amino acid is acetyl-C and this amino acid is not listed in SEQ. ID. no. 2. Regarding the sequence listed in Figures 6 and 7, said sequences are not SEQ. ID. no. 133, because the first amino acid in said sequences is butyl alanine, not Asx as listed in the sequence listing. Regarding the peptide SLF--G which is disclosed in various parts of the specification, said peptide is not SEQ. ID. no. 7 because SEQ. ID. no. 7 refers to a peptide of 7 amino acids. A new CRF needs to be submitted which discloses the aforementioned sequences.

However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/Or Amino Acid Sequence Disclosures.

Any inquiry concerning this communication should be directed to Examiner Ron Schwadron, Art Unit 1816, whose telephone number is (703) 308-4680.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

*R. Schwadron*

Ron Schwadron, Ph.D.  
August 15, 1997

RONALD B. SCHWADRON  
PRIMARY EXAMINER  
GROUP 1800